EP
MDGL icon

Elkfork Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Elkfork Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-44
Closed -$5K – 1058
2019
Q1 		$5K Hold
44
– – ﹤0.01% 1033
2018
Q4 		$5K Buy
+44
New +$6.81K ﹤0.01% 1010

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Elkfork Partners's MDGL Position: Q2 2019 in Review

Elkfork Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2019, closing a stake of 44 shares — an estimated $5K sold.

Elkfork Partners first reported a position in MDGL in Q4 2018 and held it in 2 quarters. The position peaked at $5K in Q1 2019. 116 funds tracked by Wall St. Rank hold MDGL as of Q2 2019.

  • Elkfork Partners reported no remaining Madrigal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Elkfork Partners sold 44 Madrigal Pharmaceuticals shares in Q2 2019, an estimated $5K.
  • Elkfork Partners first reported a position in Madrigal Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Elkfork Partners's Madrigal Pharmaceuticals position peaked at $5K in Q1 2019.
  • 116 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2019.

Based on Elkfork Partners's 13F filing for Q2 2019, filed 13 Aug 2019.